GPT and Cirrhosis: This analysis demonstrates the possibility of identifying those Caucasian, treatment-naive patients with CHC and HCV GT3 infection who have a high probability of achieving an SVR with PegIFN alfa-2a/RBV treatment, with a simple scoring system that uses readily available and well-known baseline predictors of response (age, bodyweight, cirrhosis status, ALT level, platelet count, and HCV RNA level).